Atara Biotherapeutics, Inc. (ATRA)
NASDAQ · Healthcare
Atara Biotherapeutics, Inc. EBITDA 2022–2025
Atara Biotherapeutics, Inc. annual/quarterly ebitda history and growth rate from 2022 to 2026. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Atara Biotherapeutics, Inc. ebitda for the quarter ending March 31, 2026 was -3.3 M, a 108.23% decrease year-over-year.
- Atara Biotherapeutics, Inc. ebitda for the twelve months ending March 31, 2026 was -66.4 M.
- Atara Biotherapeutics, Inc. annual ebitda for 2025 was 38.0 M, a 148.45% decrease from 2024.
- Atara Biotherapeutics, Inc. annual ebitda for 2024 was -78.4 M, a 71.09% decrease from 2023.
- Atara Biotherapeutics, Inc. annual ebitda for 2023 was -271.2 M, a 1.34% decrease from 2022.
- Atara Biotherapeutics, Inc. annual ebitda for 2022 was -274.9 M.
EBITDA
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Atara Biotherapeutics, Inc. EBITDA — FAQ
Atara Biotherapeutics, Inc. (ATRA) ebitda over the last 4 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see ATRA's ebitda history?
The chart and table above show Atara Biotherapeutics, Inc.'s ebitda by year and by quarter, including the growth rate.